You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The University of California and Springer Nature reach an open-access publishing deal.
Times Higher Education reports that the University of California and Elsevier may resume negotiations.
Within the master observational trial, the organizations have agreed to prospectively collect real world data and ultimately build a national oncology database.
More than two dozen University of California researchers are taking a break from their positions on the editorial boards of Elsevier journals, according to ScienceInsider.
The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.
The University of California has decided to not renew its subscription with the scientific publisher Elsevier.
Stat News reports that the University of California and publisher Elsevier are fighting over open-access journal payments.
In PNAS this week: germline variants influence tumor immune gene expression in two dozen cancer types, phylogenetic relationships of hemipteroid insects, and more.
Three studies encompassing dozens of ancient genomes are offering a closer look at complex historical population spread in North, Central, and South America.
A federal appeals court in the US has upheld a judgment that gave the Broad Institute key CRISPR patents.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.